Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer
Status: Enrolling
Updated:  4/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer
Status: Enrolling
Updated: 4/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
City of Hope South Pasadena
mi
from
South Pasadena, CA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated:  4/2/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer
Status: Enrolling
Updated: 4/2/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Hôpital St. Louis
mi
from
Paris,
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Hôpital St. Louis
mi
from
Paris,
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
White Plains Hospital Center for Cancer Care
mi
from
White Plains, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
City of Hope
mi
from
Duarte, CA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Carolina Blood and Cancer Care Associates PA
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Rush University Medical Center
mi
from
Chicago, IL
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Froedtert Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Desert Hematology Oncology Medical Group, Inc
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated:  4/3/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling
Updated: 4/3/2018
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Urological Associates of Southern Arizona, PC
mi
from
Tucson, AZ
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Urological Associates of Southern Arizona, PC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
South Florida Medical Research
mi
from
Aventura, FL
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
South Florida Medical Research
mi
from
Aventura, FL
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
AccumetRX Clinical Trials
mi
from
Albuquerque, NM
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
AccumetRX Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Associated Medical Professionals of NY (AMP of NY)
mi
from
Syracuse, NY
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Associated Medical Professionals of NY (AMP of NY)
mi
from
Syracuse, NY
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Eastern Urological Associates
mi
from
Greenville, NC
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Eastern Urological Associates
mi
from
Greenville, NC
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Urology Clinics of North Texas
mi
from
Dallas, TX
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Urology Clinics of North Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Advanced Urology Institute
mi
from
Daytona Beach, FL
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Advanced Urology Institute
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Adult Pediatric Urology, PC
mi
from
Council Bluffs, IA
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Adult Pediatric Urology, PC
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Adult and Pediatric Urology P.C
mi
from
Omaha, NE
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Adult and Pediatric Urology P.C
mi
from
Omaha, NE
Click here to add this to my saved trials
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Urologic Consultants of Southeastern Pennsylvania (UCSEPA)
mi
from
Bala-Cynwyd, PA
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Urologic Consultants of Southeastern Pennsylvania (UCSEPA)
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  4/3/2018
SCRI
mi
from
Nashville, TN
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 4/3/2018
SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  4/3/2018
Centre Leon Berard; Departement Oncologie Medicale
mi
from
Lyon,
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 4/3/2018
Centre Leon Berard; Departement Oncologie Medicale
mi
from
Lyon,
Click here to add this to my saved trials
Developing a Healthy Lifestyle in Breast Cancer Survivors
Developing a Healthy Lifestyle in Breast Cancer Survivors
Status: Enrolling
Updated:  4/3/2018
Healthy Eating and Activity Laboratory
mi
from
Knoxville, TN
Developing a Healthy Lifestyle in Breast Cancer Survivors
Developing a Healthy Lifestyle in Breast Cancer Survivors
Status: Enrolling
Updated: 4/3/2018
Healthy Eating and Activity Laboratory
mi
from
Knoxville, TN
Click here to add this to my saved trials
Prostate Biopsy Access Needle & Needle Guide Feasibility Study
Prostate Biopsy Access Needle & Needle Guide Feasibility Study
Status: Enrolling
Updated:  4/3/2018
Corbin Clinical Resources
mi
from
Cumberland, MD
Prostate Biopsy Access Needle & Needle Guide Feasibility Study
Prostate Biopsy Access Needle & Needle Guide Feasibility Study
Status: Enrolling
Updated: 4/3/2018
Corbin Clinical Resources
mi
from
Cumberland, MD
Click here to add this to my saved trials
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
Status: Enrolling
Updated:  4/3/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
Status: Enrolling
Updated: 4/3/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated:  4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Green Tea Extract in Treating Patients With Actinic Keratosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology
Status: Enrolling
Updated: 4/3/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of PTS for Patients With Solid Tumors
A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors
Status: Enrolling
Updated:  4/3/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
A Study of PTS for Patients With Solid Tumors
A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors
Status: Enrolling
Updated: 4/3/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
mi
from
Burbank, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
mi
from
Pomona, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
mi
from
Pomona, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Radiation Oncology Center - Roseville
mi
from
Roseville, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Radiation Oncology Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
General Robert Huyser Cancer Center at David Grant Medical Center
mi
from
Travis Air Force Base, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
General Robert Huyser Cancer Center at David Grant Medical Center
mi
from
Travis Air Force Base, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials